

# Guido Ferrari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1315584/publications.pdf>

Version: 2024-02-01

234  
papers

15,758  
citations

19608

61  
h-index

21474

114  
g-index

248  
all docs

248  
docs citations

248  
times ranked

11670  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. <i>New England Journal of Medicine</i> , 2012, 366, 1275-1286.	13.9	1,699
2	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2009, 206, 1253-1272.	4.2	562
3	Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. <i>Nature</i> , 2012, 482, 89-93.	13.7	452
4	Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. <i>Science Translational Medicine</i> , 2014, 6, 228ra39.	5.8	412
5	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	6.6	374
6	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9019-9024.	3.3	371
7	Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. <i>Journal of Virology</i> , 2012, 86, 11521-11532.	1.5	357
8	Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. <i>Aids</i> , 2009, 23, 897-906.	1.0	305
9	A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. <i>Journal of Immunological Methods</i> , 2002, 260, 157-172.	0.6	299
10	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. <i>Cell</i> , 2014, 158, 481-491.	13.5	266
11	Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity. <i>Journal of Virology</i> , 2014, 88, 2633-2644.	1.5	237
12	Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 1396-1401.	3.3	231
13	An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum. <i>Journal of Virology</i> , 2011, 85, 7029-7036.	1.5	210
14	High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediated antibody responses. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2011, 79A, 603-612.	1.1	197
15	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016, 22, 762-770.	15.2	197
16	Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. <i>Blood</i> , 2011, 117, 4805-4815.	0.6	193
17	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	6.0	191
18	Near Full-Length Clones and Reference Sequences for Subtype C Isolates of HIV Type 1 from Three Different Continents. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 161-168.	0.5	182

#	ARTICLE	IF	CITATIONS
19	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. <i>Journal of Virology</i> , 2014, 88, 7715-7726.	1.5	169
20	Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. <i>Journal of Clinical Investigation</i> , 2013, 123, 380-93.	3.9	165
21	HIV Evolution in Early Infection: Selection Pressures, Patterns of Insertion and Deletion, and the Impact of APOBEC. <i>PLoS Pathogens</i> , 2009, 5, e1000414.	2.1	161
22	Lack of infection in HIV-exposed individuals is associated with a strong CD8+ cell noncytotoxic anti-HIV response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 1030-1035.	3.3	149
23	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	2.1	145
24	Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection. <i>Journal of Virology</i> , 2011, 85, 10518-10528.	1.5	141
25	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014, 505, 502-508.	13.7	140
26	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	5.8	137
27	T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. <i>Immunity</i> , 2012, 37, 1-2.	6.6	131
28	Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. <i>Nature Medicine</i> , 2012, 18, 1673-1681.	15.2	130
29	Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV <sub>mac251</sub> Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial. <i>Journal of Virology</i> , 2013, 87, 1708-1719.	1.5	130
30	Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4512-4517.	3.3	126
31	Curing HIV: Seeking to Target and Clear Persistent Infection. <i>Cell</i> , 2020, 181, 189-206.	13.5	126
32	Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. <i>Journal of Clinical Investigation</i> , 2015, 125, 4077-4090.	3.9	124
33	Discriminating between latent and active tuberculosis with multiple biomarker responses. <i>Tuberculosis</i> , 2011, 91, 250-256.	0.8	123
34	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	13.7	117
35	Perforin and IL-2 Upregulation Define Qualitative Differences among Highly Functional Virus-Specific Human CD8+ T Cells. <i>PLoS Pathogens</i> , 2010, 6, e1000798.	2.1	111
36	Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination. <i>Journal of Virology</i> , 2010, 84, 4998-5006.	1.5	110

#	ARTICLE	IF	CITATIONS
37	Prevention of Infection by a Granulocyte-Macrophage Colony-Stimulating Factor Co-Expressing DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. <i>Journal of Infectious Diseases</i> , 2011, 204, 164-173.	1.9	105
38	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , 2017, 14, e1002435.	3.9	104
39	Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 203-212.	0.9	101
40	Measurement of cytokine release at the single cell level using the ELISPOT assay. <i>Methods</i> , 2006, 38, 274-282.	1.9	100
41	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 3879-3890.	3.9	99
42	Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal <i>Ex Vivo</i> . <i>Journal of Virology</i> , 2018, 92, .	1.5	96
43	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	3.9	95
44	Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection. <i>PLoS Pathogens</i> , 2011, 7, e1001273.	2.1	90
45	Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. <i>Blood Advances</i> , 2017, 1, 2329-2342.	2.5	90
46	3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. <i>Science Immunology</i> , 2020, 5, .	5.6	90
47	HIV-Specific Functional Antibody Responses in Breast Milk Mirror Those in Plasma and Are Primarily Mediated by IgG Antibodies. <i>Journal of Virology</i> , 2011, 85, 9555-9567.	1.5	86
48	Results of an ELISPOT Proficiency Panel Conducted in 11 Laboratories Participating in International Human Immunodeficiency Virus Type 1 Vaccine Trials. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 68-81.	0.5	85
49	Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. <i>Vaccine</i> , 2007, 25, 510-518.	1.7	85
50	Epitope Specificity of Human Immunodeficiency Virus-1 Antibody Dependent Cellular Cytotoxicity [ADCC] Responses. <i>Current HIV Research</i> , 2013, 11, 378-387.	0.2	82
51	Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques. <i>Journal of Virology</i> , 2014, 88, 3329-3339.	1.5	80
52	Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. <i>Cell Reports</i> , 2018, 25, 107-117.e3.	2.9	79
53	Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 15, 36-47.	2.3	79
54	RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. <i>Cell</i> , 2018, 175, 387-399.e17.	13.5	78

#	ARTICLE	IF	CITATIONS
55	Induction of Plasma (TRAIL), TNFR-2, Fas Ligand, and Plasma Microparticles after Human Immunodeficiency Virus Type 1 (HIV-1) Transmission: Implications for HIV-1 Vaccine Design. <i>Journal of Virology</i> , 2008, 82, 7700-7710.	1.5	76
56	HIV-1 gp120 Vaccine Induces Affinity Maturation in both New and Persistent Antibody Clonal Lineages. <i>Journal of Virology</i> , 2012, 86, 7496-7507.	1.5	76
57	High Antibody-Dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers. <i>PLoS ONE</i> , 2013, 8, e74855.	1.1	76
58	Prolonged CD4+Cell/Virus Load Discordance during Treatment with Protease Inhibitor-Based Highly Active Antiretroviral Therapy: Immune Response and Viral Control. <i>Journal of Infectious Diseases</i> , 2003, 187, 1027-1037.	1.9	71
59	A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies. <i>Journal of Virology</i> , 2016, 90, 2127-2134.	1.5	69
60	Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. <i>Journal of Clinical Investigation</i> , 2015, 125, 2702-2706.	3.9	68
61	Thinking Outside the Gate: Single-Cell Assessments in Multiple Dimensions. <i>Immunity</i> , 2015, 42, 591-592.	6.6	67
62	High-Dose Recombinant Canarypox Vaccine Expressing HIV-1 Protein, in Seronegative Human Subjects. <i>Journal of Infectious Diseases</i> , 2005, 192, 1249-1259.	1.9	66
63	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	5.1	66
64	Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy. <i>PLoS ONE</i> , 2011, 6, e19617.	1.1	65
65	CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection. <i>Journal of Immunology</i> , 2012, 188, 4289-4296.	0.4	63
66	Progress in HIV-1 vaccine development. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 3-10.	1.5	62
67	Standardization and Validation Issues of the ELISPOT Assay. , 2005, 302, 051-086.		60
68	SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. <i>Vaccine</i> , 2012, 30, 1737-1745.	1.7	60
69	Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees. <i>Journal of Virology</i> , 2013, 87, 7828-7836.	1.5	59
70	<sc>HIV</sc> antibodies for treatment of <sc>HIV</sc> infection. <i>Immunological Reviews</i> , 2017, 275, 313-323.	2.8	59
71	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. <i>Lancet HIV</i> , 2020, 7, e688-e698.	2.1	58
72	Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. <i>Journal of Immunological Methods</i> , 2010, 363, 42-50.	0.6	57

#	ARTICLE	IF	CITATIONS
73	Infant HIV Type 1 gp120 Vaccination Elicits Robust and Durable Anti-V1V2 Immunoglobulin G Responses and Only Rare Envelope-Specific Immunoglobulin A Responses. <i>Journal of Infectious Diseases</i> , 2015, 211, 508-517.	1.9	57
74	Initial HIV-1 Antigen-Specific CD8 <sup>+</sup> T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus Replication. <i>Journal of Virology</i> , 2012, 86, 6835-6846.	1.5	56
75	Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. <i>Vaccine</i> , 2009, 27, 243-249.	1.7	55
76	Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. <i>Journal of Virology</i> , 2015, 89, 9952-9961.	1.5	55
77	Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. <i>Vaccine</i> , 2008, 26, 215-223.	1.7	53
78	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. <i>Science Immunology</i> , 2021, 6, .	5.6	53
79	IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). <i>Clinical and Experimental Immunology</i> , 1995, 101, 239-248.	1.1	52
80	Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIV <sub>mac251</sub> at Challenge Exposure. <i>Journal of Virology</i> , 2013, 87, 3538-3548.	1.5	52
81	Performance of serum-supplemented and serum-free media in IFN $\gamma$ Elispot Assays for human T cells. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 609-618.	2.0	51
82	Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 823-834.	21.5	51
83	Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. <i>Retrovirology</i> , 2012, 9, 89.	0.9	50
84	Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. <i>PLoS Pathogens</i> , 2020, 16, e1008083.	2.1	50
85	Oligoclonal CD8 Lymphocytes from Persons with Asymptomatic Human Immunodeficiency Virus (HIV) Type 1 Infection Inhibit HIV-1 Replication. <i>Journal of Infectious Diseases</i> , 1995, 172, 964-973.	1.9	49
86	Identification of Highly Conserved and Broadly Cross-Reactive HIV Type 1 Cytotoxic T Lymphocyte Epitopes as Candidate Immunogens for Inclusion in Mycobacterium bovis BCG-Vectored HIV Vaccines. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1433-1443.	0.5	49
87	Excellent Safety and Tolerability of the Human Immunodeficiency Virus Type 1 pGA2/JS2 Plasmid DNA Priming Vector Vaccine in HIV Type 1 Uninfected Adults. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 678-683.	0.5	49
88	Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 505-508.	0.9	49
89	A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. <i>Vaccine</i> , 2011, 29, 1948-1958.	1.7	48
90	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 296ra112.	5.8	47

#	ARTICLE	IF	CITATIONS
91	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <i>EBioMedicine</i> , 2016, 14, 97-111.	2.7	47
92	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	46
93	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. <i>Npj Vaccines</i> , 2021, 6, 50.	2.9	46
94	CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 3503-8.	3.3	46
95	Loss of DNAM-1 contributes to CD8 <sup>+</sup> T cell exhaustion in chronic HIV-1 infection. <i>European Journal of Immunology</i> , 2010, 40, 949-954.	1.6	45
96	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018, 92, .	1.5	45
97	Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. <i>Journal of Immunology</i> , 2016, 197, 4603-4612.	0.4	44
98	Effect of Highly Active Antiretroviral Therapy and Thymic Transplantation on Immunoreconstitution in HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 403-413.	0.5	43
99	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , the, 2019, 6, e737-e749.	2.1	43
100	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020, 31, 107624.	2.9	43
101	Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses. <i>PLoS Pathogens</i> , 2015, 11, e1004658.	2.1	42
102	Potent Functional Antibody Responses Elicited by HIV-1 DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults. <i>PLoS ONE</i> , 2015, 10, e0118486.	1.1	42
103	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. <i>Molecular Therapy</i> , 2016, 24, 2021-2032.	3.7	41
104	Control of Heterologous Simian Immunodeficiency Virus SIV <sub>smE660</sub> Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	39
105	Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	39
106	Mucosal Immunization of Lactating Female Rhesus Monkeys with a Transmitted/Founder HIV-1 Envelope Induces Strong Env-Specific IgA Antibody Responses in Breast Milk. <i>Journal of Virology</i> , 2013, 87, 6986-6999.	1.5	38
107	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. <i>PLoS Pathogens</i> , 2017, 13, e1006182.	2.1	38
108	Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study. <i>PLoS ONE</i> , 2016, 11, e0152038.	1.1	37

#	ARTICLE	IF	CITATIONS
109	Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. <i>Frontiers in Immunology</i> , 2019, 10, 1025.	2.2	37
110	Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. <i>Journal of Virology</i> , 2019, 93, .	1.5	37
111	Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. <i>PLoS Pathogens</i> , 2020, 16, e1008764.	2.1	37
112	Beyond Viral Neutralization. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 760-764.	0.5	36
113	The Human Antibody Response to the Surface of <i>Mycobacterium tuberculosis</i> . <i>PLoS ONE</i> , 2014, 9, e98938.	1.1	35
114	Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C $\beta$ . <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8638-8646.	2.9	35
115	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8525-8539.	1.5	35
116	Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. <i>Expert Review of Vaccines</i> , 2006, 5, 505-516.	2.0	34
117	Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. <i>Journal of Immunology</i> , 2014, 193, 6172-6183.	0.4	34
118	Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. <i>Journal of Immunological Methods</i> , 2014, 409, 107-116.	0.6	34
119	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. <i>Journal of Immunology</i> , 2016, 197, 2726-2737.	0.4	34
120	Acute HIV-1 Infection in the Southeastern United States: A Cohort Study. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 121-128.	0.5	33
121	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 1280-1288.	1.9	32
122	Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum. <i>PLoS ONE</i> , 2012, 7, e37648.	1.1	30
123	A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	30
124	SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	30
125	In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1 neutralizing activity. <i>Journal of Clinical Investigation</i> , 2020, 130, 827-837.	3.9	30
126	Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. <i>Journal of Virology</i> , 2017, 91, .	1.5	29



#	ARTICLE	IF	CITATIONS
127	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. <i>PLoS ONE</i> , 2017, 12, e0179597.	1.1	29
128	Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. <i>Vaccine Journal</i> , 2017, 24, .	3.2	28
129	DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. <i>Journal of Clinical Investigation</i> , 2019, 129, 4769-4785.	3.9	27
130	CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition. <i>Immunology Letters</i> , 2001, 79, 37-45.	1.1	26
131	Absence of Immunodominant Anti-Gag p17 (SL9) Responses among Gag CTL-Positive, HIV-Uninfected Vaccine Recipients Expressing the HLA-A*0201 Allele. <i>Journal of Immunology</i> , 2004, 173, 2126-2133.	0.4	26
132	Aggregate complexes of HIV-1 induced by multimeric antibodies. <i>Retrovirology</i> , 2014, 11, 78.	0.9	26
133	Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. <i>Journal of Virology</i> , 2016, 90, 10362-10378.	1.5	26
134	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. <i>Journal of Virology</i> , 2017, 91, .	1.5	26
135	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. <i>Communications Biology</i> , 2018, 1, 134.	2.0	26
136	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. <i>Journal of Virology</i> , 2019, 93, .	1.5	26
137	Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. <i>Aids</i> , 2011, 25, 941-949.	1.0	25
138	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2741.	2.2	25
139	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. <i>Journal of Virology</i> , 2019, 93, .	1.5	25
140	Robust antibody and cellular responses induced by DNA-only vaccination for HIV. <i>JCI Insight</i> , 2020, 5, .	2.3	25
141	Distinct Kinetics of Gag-Specific CD4+ and CD8+ T Cell Responses during Acute HIV-1 Infection. <i>Journal of Immunology</i> , 2012, 188, 2198-2206.	0.4	24
142	Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs. <i>Journal of Immunological Methods</i> , 2014, 409, 99-106.	0.6	24
143	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. <i>Journal of Virology</i> , 2016, 90, 4951-4965.	1.5	23
144	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. <i>Journal of Virology</i> , 2017, 91, .	1.5	23

#	ARTICLE	IF	CITATIONS
145	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. <i>Cell Reports</i> , 2018, 25, 3123-3135.e6.	2.9	23
146	The Impact of HIV-1 Infection on Phenotypic and Functional Parameters of Cellular Immunity in Chimpanzees. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 647-656.	0.5	22
147	Comparison of Systemic and Mucosal Immunization with Helper-Dependent Adenoviruses for Vaccination against Mucosal Challenge with SHIV. <i>PLoS ONE</i> , 2013, 8, e67574.	1.1	22
148	Transcriptional and Posttranscriptional Regulation of Cytokine Gene Expression in HIV-1 Antigen-Specific CD8 <sup>+</sup> T Cells That Mediate Virus Inhibition. <i>Journal of Virology</i> , 2014, 88, 9514-9528.	1.5	22
149	The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN- $\gamma$ ELISpot) assay. <i>Journal of Immunological Methods</i> , 2014, 409, 31-43.	0.6	22
150	Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. <i>PLoS ONE</i> , 2016, 11, e0155702.	1.1	22
151	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. <i>Journal of Virology</i> , 2016, 90, 4133-4149.	1.5	22
152	Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 880-888.	0.5	22
153	Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. <i>Journal of Infectious Diseases</i> , 2017, 215, S152-S159.	1.9	22
154	Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. <i>Journal of Infectious Diseases</i> , 2022, 225, 856-861.	1.9	22
155	Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2020, 130, 5157-5170.	3.9	22
156	Monkeying Around: Using Non-human Primate Models to Study NK Cell Biology in HIV Infections. <i>Frontiers in Immunology</i> , 2019, 10, 1124.	2.2	21
157	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. <i>Cell Reports</i> , 2020, 30, 1553-1569.e6.	2.9	21
158	Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 169-176.	1.5	20
159	Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. <i>Frontiers in Immunology</i> , 2019, 10, 2875.	2.2	20
160	Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. <i>PLoS ONE</i> , 2016, 11, e0153484.	1.1	20
161	The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved Human Peripheral Blood Mononuclear Cells. <i>Journal of Immunological Methods</i> , 2014, 409, 21-30.	0.6	19
162	The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostrum B cells. <i>Mucosal Immunology</i> , 2016, 9, 414-427.	2.7	19

#	ARTICLE	IF	CITATIONS
163	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. <i>Journal of Virology</i> , 2020, 94, .	1.5	19
164	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. <i>PLoS Pathogens</i> , 2021, 17, e1009363.	2.1	19
165	Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1. <i>Aids</i> , 2001, 15, W1-W25.	1.0	18
166	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 859-868.	0.5	18
167	Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 436-447.	1.1	18
168	Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques. <i>Journal of Virology</i> , 2019, 93, .	1.5	18
169	HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. <i>JCI Insight</i> , 2020, 5, .	2.3	18
170	Naïve T Cells Are Maintained in the Periphery During the First 3 Months of Acute HIV-1 Infection: Implications for Analysis of Thymus Function. <i>Journal of Clinical Immunology</i> , 2005, 25, 462-472.	2.0	17
171	Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 193-205.	0.5	17
172	Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques. <i>MSphere</i> , 2018, 3, .	1.3	17
173	Antibody Fab properties outperform titer in predictive models of SIV vaccine-induced protection. <i>Molecular Systems Biology</i> , 2019, 15, e8747.	3.2	17
174	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. <i>Journal of Virology</i> , 2014, 88, 9406-9417.	1.5	16
175	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. <i>IScience</i> , 2021, 24, 102047.	1.9	16
176	Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses. <i>Clinical and Experimental Immunology</i> , 2007, 149, 211-216.	1.1	15
177	Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys. <i>Mucosal Immunology</i> , 2018, 11, 1716-1726.	2.7	15
178	A Cluster of HIV Type 1 Subtype C Sequences from Ethiopia, Observed in Full Genome Analysis, Is Not Sustained in Subgenomic Regions. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1125-1133.	0.5	14
179	Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. <i>Vaccine</i> , 2012, 30, 1830-1840.	1.7	14
180	An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 9154-9166.	1.5	14

#	ARTICLE	IF	CITATIONS
181	Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus. <i>Nature Communications</i> , 2016, 7, 12131.	5.8	14
182	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. <i>Communications Biology</i> , 2022, 5, 271.	2.0	14
183	Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. <i>Journal of Virology</i> , 2016, 90, 8644-8660.	1.5	13
184	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. <i>Journal of Virology</i> , 2019, 93, .	1.5	13
185	Oral Coadministration of an Intramuscular DNA/Modified Vaccinia Ankara Vaccine for Simian Immunodeficiency Virus Is Associated with Better Control of Infection in Orally Exposed Infant Macaques. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 310-325.	0.5	12
186	HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians. <i>Human Immunology</i> , 2004, 65, 648-659.	1.2	11
187	Longitudinal Assessment of Immune Response and Viral Characteristics in HIV-Infected Patients with Prolonged CD4+/Viral Load Discordance. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 13-16.	0.5	11
188	Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 678511.	2.2	11
189	Immunodominance and Cross-Reactivity of B5703-Restricted CD8 T Lymphocytes from HIV Type 1 Subtype C-Infected Ethiopians. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 239-245.	0.5	10
190	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , 2018, 92, .	1.5	10
191	Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART <sup>®</sup> Molecules. <i>Frontiers in Immunology</i> , 2020, 11, 713.	2.2	10
192	Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. <i>JCI Insight</i> , 2016, 1, e88522.	2.3	10
193	Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
194	An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques. <i>Vaccine Journal</i> , 2017, 24, .	3.2	8
195	Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site. <i>Journal of Virology</i> , 2017, 91, .	1.5	8
196	DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. <i>Vaccine</i> , 2017, 35, 929-937.	1.7	7
197	HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers. <i>Scientific Reports</i> , 2019, 9, 10165.	1.6	7
198	Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period. <i>Journal of Infectious Diseases</i> , 2019, 219, 1755-1765.	1.9	7

#	ARTICLE	IF	CITATIONS
199	Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers. <i>Microorganisms</i> , 2020, 8, 1722.	1.6	7
200	CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses. <i>Vaccines</i> , 2020, 8, 284.	2.1	7
201	Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. <i>Retrovirology</i> , 2021, 18, 35.	0.9	7
202	Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. <i>Journal of Virology</i> , 2021, , JVI0164321.	1.5	7
203	Variability of the IFN- $\gamma$ ELISpot assay in the context of proficiency testing and bridging studies. <i>Journal of Immunological Methods</i> , 2016, 433, 69-76.	0.6	6
204	Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial. <i>MBio</i> , 2020, 11, .	1.8	6
205	Engineering antibody-based molecules for HIV treatment and cure. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 290-299.	1.5	6
206	HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy. <i>MSphere</i> , 2020, 5, .	1.3	6
207	ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. <i>PLoS Pathogens</i> , 2021, 17, e1010046.	2.1	6
208	Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. <i>Journal of Virology</i> , 2017, 91, .	1.5	5
209	Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 95, .	1.5	5
210	Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of the HIV-1 Envelope to Elicit a Cross-Clade Response with Potent Fc-Effector Functions. <i>Vaccines</i> , 2021, 9, 975.	2.1	5
211	Massive CD8 T Cell Response to Primary HIV Infection in the Setting of Severe Clinical Presentation. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 789-792.	0.5	4
212	Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. <i>Aids</i> , 2016, 30, 2815-2822.	1.0	4
213	Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. <i>Aids</i> , 2020, 34, 1923-1931.	1.0	4
214	Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART <sup>®</sup> Molecules. <i>Frontiers in Immunology</i> , 2021, 12, 710273.	2.2	4
215	Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges. <i>Frontiers in Immunology</i> , 2022, 13, 788619.	2.2	4
216	Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulation. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, , .	1.1	4

#	ARTICLE	IF	CITATIONS
217	Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine. <i>Viruses</i> , 2017, 9, 135.	1.5	3
218	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. <i>Vaccine</i> , 2021, 39, 3879-3891.	1.7	3
219	Tandem bispecific broadly neutralizing antibody "a novel approach to HIV-1 treatment. <i>Journal of Clinical Investigation</i> , 2018, 128, 2189-2191.	3.9	3
220	Modulation of RAS Pathways as a Biomarker of Protection against HIV and as a Means to Improve Vaccine Efficacy. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A99-A99.	0.5	2
221	Teaching advanced flow cytometry in Africa: 10 years of lessons learned. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016, 89, 971-974.	1.1	2
222	A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. <i>Retrovirology</i> , 2017, 14, 46.	0.9	2
223	Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy138.	0.4	2
224	A Cytometrist's Guide to Coordinating and Performing Effective COVID-19 Research. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 11-18.	1.1	2
225	Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV. <i>Npj Vaccines</i> , 2022, 7, 18.	2.9	2
226	Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection. <i>MSphere</i> , 2022, 7, e0083921.	1.3	2
227	Endpoint Assays in HIV-1 Vaccine Trials: Functioning in a Good Laboratory Practices Environment. , , 239-275.		1
228	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX <sup>®</sup> B/E in RV144 Vaccinees. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A36-A36.	0.5	1
229	A-102 Antibody binding to HIV-1 infected cells as mechanism for treatment of HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 33-33.	0.9	1
230	Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s. <i>Frontiers in Immunology</i> , 2021, 12, 787603.	2.2	1
231	Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain. <i>Science Advances</i> , 2022, 8, eabm3948.	4.7	1
232	Response to Comment on "CD4+CD8+T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection" <i>Journal of Immunology</i> , 2012, 188, 5809.2-5810.	0.4	0
233	Co-Administration of HIV Env Protein with DNA and/or NYVAC Vaccines in Humans Results in Earlier and Potent Generation of Anti-Env Antibody Responses. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
234	Anti-V2 Antibodies Virus Vulnerability Revealed by Envelope V1 Deletion in HIV Vaccine Candidates. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0